Why AngioDynamics Stock Is Sinking Today

• The aesculapian exertion institution announced the status of CEO Jim Clemmer.

• This quality creates uncertainty for AngioDynamics -- and investors dislike uncertainty.

• However, the company's concern appears to beryllium improving.

• 10 stocks we similar amended than AngioDynamics ›

Shares of AngioDynamics (NASDAQ: ANGO) were sinking 13.1% arsenic of 11:02 a.m. ET. The sell-off came aft the aesculapian exertion institution announced its third-quarter results earlier the marketplace open.

Those results were really rather good. AngioDynamics reported Q3 gross of $79.4 million, up 8.8% year-over-year connected a pro forma ground and higher than the statement Wall Street estimation of $76.4 million. The institution posted an adjusted nonaccomplishment of $59,000, which amounted to astir $0.00 per share. Analysts expected an adjusted nett nonaccomplishment of $0.10 per share.

So wherefore did this aesculapian instrumentality banal merchantability disconnected truthful heavily? Probably due to the fact that AngioDynamics announced the unexpected status of CEO Jim Clemmer.

Clemmer has led AngioDynamics since 2016. In a connection released successful the company's Q3 property release, helium said, "After 10 years astatine AngioDynamics, I consciousness acceptable to determination connected to the adjacent section of my life."

His determination to discontinue amazed investors – and, seemingly, AngioDynamics' committee of directors arsenic well. The committee didn't person a successor already lined up. Instead, it has formed a hunt committee to "conduct a broad search" for the adjacent CEO, with assistance from an enforcement hunt firm.

Investors dislike uncertainty. Clemmer's departure creates uncertainty for AngioDynamics.

However, Clemmer doesn't look to beryllium abandoning vessel due to the fact that he's acrophobic that it's sinking. He volition proceed to pb the institution until his replacement is found.

Also, speech from the quality astir Clemmer, things look to beryllium looking up for AngioDynamics. The institution accrued its nett income and adjusted EBITDA guidance for fiscal twelvemonth 2026. It precocious received U.S. Food and Drug Administration (FDA) clearance for a modified AlphaVac F1885 System and 2 FDA Investigational Device Exemption (IDE) approvals.

Should investors bargain this banal connected the dip? I deliberation the sell-off is overdone. However, different stocks connection much charismatic risk-reward propositions, successful my view.

Before you bargain banal successful AngioDynamics, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and AngioDynamics wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.